Литература.Механизм действия.Hyman SE, Nestler EJ. Molecular foundations of psychiatry. Washington, DC: American Psychiatric Press, 1993. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999; 156:286. Nyberg S, Eriksson B, Oxenstierna G, et al. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry 1999; 156:869. Tamminga CA. Principles of the pharmacotherapy of schizophrenia. In: Charney DS, Nestler EJ, Bunnery BS, eds. Neurobiology of mental illness. New York: Oxford University Press, 1999. Шизофрения и шизоаффективное расстройство.American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154 (4 suppl). Breier A, Buchanan RW, Kirkpatrick B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151:20. Carlsson A, Waters N, Carlsson ML. Neurotransmitter interactions in schizophrenia-therapeutic implications. Biol Psychiatry 1999; 46:1388. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-refractory schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789. Kane JM. Pharmacologic treatment of schizophrenia. Biol Psychiatry 1999; 46:1396. Harder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825. Robinson DG, Woerner MG, Alvir JMJ, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999; 156:544. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997; 54:549. Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154:457. Viguera AC, Baldessarini RJ, Hegarty JM, et al. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 1997; 54:49. Аффективные расстройства.Tohen M, Sanger TM, McElroy SL, et al. Olanzepine versus placebo in the treatment of acute mania. Am J Psychiatry 1999; 156:702. Zarate СA, Tohen M, Baldessarini RJ. Clozapine in severe mood disorders. J Clin Psychiatry 1995; 56:411. — 51 —
|